Search research articles
Contact Us
Filters
Showing results (51-60 of 54) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 54 results.
Cancer Discovery
|
July 18, 2018
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Limo Chen, Lixia Diao, Yongbin Yang, et al.
Genome Biology
|
November 5, 2020
Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity
Won-Chul Lee, Alexandre Reuben, Xin Hu, et al.
Science Translational Medicine
|
September 3, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer
Kathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker, et al.
Nature Communications
|
November 25, 2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence
Melinda Soeung, Xinmiao Yan, Ciro Zanca, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 54) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 54 results.
Cancer Discovery
|
July 18, 2018
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Limo Chen, Lixia Diao, Yongbin Yang, et al.
Genome Biology
|
November 5, 2020
Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity
Won-Chul Lee, Alexandre Reuben, Xin Hu, et al.
Science Translational Medicine
|
September 3, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer
Kathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker, et al.
Nature Communications
|
November 25, 2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence
Melinda Soeung, Xinmiao Yan, Ciro Zanca, et al.
Page
of 6